Clinical impact of circulating biomarkers in prediction of adverse cardiac events in patients with congenital heart disease. A systematic review
(2025) In International Journal of Cardiology 421.- Abstract
- Introduction
Patients with congenital heart disease (ConHD) are at increased risk for adverse cardiac events. Predicting long-term outcomes and guidance of patient management might benefit from a range of (new) biomarkers. This is a rapidly evolving field with potentially large consequences for clinical decision making. With a systematic review of available biomarkers in ConHD we identified the clinical role of these markers, knowledge gaps and future research directions.
Methods
We systematically reviewed the literature on associations between blood biomarkers and outcome measures (mortality or composite adverse outcomes in patients with ConHD.
Results
The inclusion criteria were met by 102 articles. Biomarkers... (More) - Introduction
Patients with congenital heart disease (ConHD) are at increased risk for adverse cardiac events. Predicting long-term outcomes and guidance of patient management might benefit from a range of (new) biomarkers. This is a rapidly evolving field with potentially large consequences for clinical decision making. With a systematic review of available biomarkers in ConHD we identified the clinical role of these markers, knowledge gaps and future research directions.
Methods
We systematically reviewed the literature on associations between blood biomarkers and outcome measures (mortality or composite adverse outcomes in patients with ConHD.
Results
The inclusion criteria were met by 102 articles. Biomarkers assessed in more than studies are discussed in the main text, those studied in 3 or less studies are summarized in the supplement. Thus, we discuss 15 biomarkers from 92 studies. These biomarkers were studied in 32,399 / 10,735 patients for the association with mortality and composite adverse outcomes, respectively. Biomarkers that were studied most and had statistically significant associations with mortality or composite adverse outcomes were (NT-pro)BNP, MELD-XI score, Hs-CRP, creatinine, albumin and sodium. Most of these biomarkers are involved in intracardiac processes associated with inflammation or are markers of renal function.
Conclusion
For (NT-pro)BNP, clinical value for prediction of mortality and composite adverse outcomes in adult and paediatric ConHD has been shown. For MELD-XI, hs-CRP, albumin, creatinine, sodium, RDW, and GDF-15, correlations with mortality and composite adverse outcomes have been demonstrated in patient groups with mixed types of ConHD, but clinical utility needs additional exploration. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8721405c-a60c-4481-879c-24189db715b6
- author
- author collaboration
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Cardiology
- volume
- 421
- article number
- 132723
- publisher
- Elsevier
- external identifiers
-
- pmid:39532255
- scopus:85212534068
- ISSN
- 0167-5273
- DOI
- 10.1016/j.ijcard.2024.132723
- language
- English
- LU publication?
- yes
- id
- 8721405c-a60c-4481-879c-24189db715b6
- date added to LUP
- 2024-11-11 17:32:42
- date last changed
- 2025-04-04 15:25:47
@article{8721405c-a60c-4481-879c-24189db715b6, abstract = {{Introduction<br/>Patients with congenital heart disease (ConHD) are at increased risk for adverse cardiac events. Predicting long-term outcomes and guidance of patient management might benefit from a range of (new) biomarkers. This is a rapidly evolving field with potentially large consequences for clinical decision making. With a systematic review of available biomarkers in ConHD we identified the clinical role of these markers, knowledge gaps and future research directions.<br/>Methods<br/>We systematically reviewed the literature on associations between blood biomarkers and outcome measures (mortality or composite adverse outcomes in patients with ConHD.<br/>Results<br/>The inclusion criteria were met by 102 articles. Biomarkers assessed in more than studies are discussed in the main text, those studied in 3 or less studies are summarized in the supplement. Thus, we discuss 15 biomarkers from 92 studies. These biomarkers were studied in 32,399 / 10,735 patients for the association with mortality and composite adverse outcomes, respectively. Biomarkers that were studied most and had statistically significant associations with mortality or composite adverse outcomes were (NT-pro)BNP, MELD-XI score, Hs-CRP, creatinine, albumin and sodium. Most of these biomarkers are involved in intracardiac processes associated with inflammation or are markers of renal function.<br/>Conclusion<br/>For (NT-pro)BNP, clinical value for prediction of mortality and composite adverse outcomes in adult and paediatric ConHD has been shown. For MELD-XI, hs-CRP, albumin, creatinine, sodium, RDW, and GDF-15, correlations with mortality and composite adverse outcomes have been demonstrated in patient groups with mixed types of ConHD, but clinical utility needs additional exploration.}}, author = {{van Genuchten, W.J. and Averesch, H. and van Dieren, Q.M. and Bonnet, D. and Odermarsky, Michal and Beghetti, Maurice and Roos-Hesselink, J.W. and Reinhardt, Z. and Male, Christoph and Naumburg, E. and Boersma, E. and De Wolf, D. and Helbing, W.A.}}, issn = {{0167-5273}}, language = {{eng}}, publisher = {{Elsevier}}, series = {{International Journal of Cardiology}}, title = {{Clinical impact of circulating biomarkers in prediction of adverse cardiac events in patients with congenital heart disease. A systematic review}}, url = {{http://dx.doi.org/10.1016/j.ijcard.2024.132723}}, doi = {{10.1016/j.ijcard.2024.132723}}, volume = {{421}}, year = {{2025}}, }